

Figure 7 Interleukin-6 (*IL-6*) messenger RNA (mRNA) expression was determined in the (a) RNA extracted from the mouse liver, (b) mouse primary hepatocytes or (c) HepG2 cells treated with interferon α (IFN α) ($n = 5$ in each group). Expression levels of *IL-6* mRNA, shown as the relative expression levels calculated by normalization using 18S expression, and presented as n -fold changes. IFN α administration did not alter *IL-6* mRNA expression in either cell.

marrow showed a decrease in cell number (data not shown), suggesting that 10⁵ IU/day IFN α may have been too high.

In addition, there might be another speculation. The gene expressions of *TfR1*, *TfR2*, *DMT1*, and *ferritin heavy chain* in the liver seemed to be slightly upregulated when 10⁴ IU/day IFN α was administered, although we did not observe any statistical significance (Fig. 2). Upregulation of *TfR1*, *TfR2*, and *DMT1* might increase iron uptake, and the increase of ferritin heavy chain implies iron accumulation in the liver, arising the possibility that the accumulation of slight changes of several molecules involved in iron uptake may partly contribute to the decrease of serum iron when 10⁴ IU/day IFN α was administered. This should be only one

possibility because we did not see any stainable iron overload in the liver even when 10⁴ IU/day IFN α was administered for 3 days. Further investigation should be needed to clarify if there is the increase of iron uptake by the liver when 10⁴ IU/day IFN α was administered, although the change of stainable iron level cannot be detected.

In clinical situations, various drugs are also used with IFN. For instance, ribavirin is now widely used for treatment of chronic hepatitis C with IFN and is known to cause hemolysis, leading to an alteration of iron metabolism. However, our results showed that IFN itself increases hepcidin expression; therefore, it is important to evaluate iron homeostasis during treatment to decide which drug is responsible for the iron dysregulations that may occur. It is also important to take IFN α -induced hepcidin upregulation into consideration.

Acknowledgment

We thank Dr. Philip Aisen for reviewing this manuscript.

References

- Andrews NC. Disorders of iron metabolism. *N. Engl. J. Med.* 1999; **341**: 1986–95.
- Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. *Cell* 2004; **117**: 285–97.
- Andrews NC. Forging a field: the golden age of iron biology. *Blood* 2008; **112**: 219–30.
- Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. *Cell* 2010; **142**: 24–38.
- Ganz T. Hepcidin and iron regulation, 10 years later. *Blood* 2011; **117**: 4425–33.
- Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2006; **290**: G199–203.
- Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. *J. Biol. Chem.* 2001; **276**: 7806–10.
- Krause A, Neitz S, Mägert HJ *et al.* LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. *FEBS Lett.* 2000; **480**: 147–50.
- Nemeth E, Tuttle MS, Powelson J *et al.* Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science* 2004; **306**: 2090–3.
- Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. *Gastroenterology* 2010; **139**: 393–408. 408.e1–2.
- Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. *Blood* 2003; **101**: 2461–3.
- Nemeth E, Rivera S, Gabayan V *et al.* IL-6 mediates hypoferrremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. *J. Clin. Invest.* 2004; **113**: 1271–6.
- Inamura J, Ikuta K, Jimbo J *et al.* Upregulation of hepcidin by interleukin-1 β in human hepatoma cell lines. *Hepatol. Res.* 2005; **33**: 198–205.
- Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and pathophysiology of iron overload. *Int. J. Hematol.* 2008; **88**: 7–15.

- 15 Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance. *World J. Gastroenterol.* 2007; **13**: 4699–706.
- 16 Nagashima M, Kudo M, Chung H *et al.* Regulatory failure of serum prohepcidin levels in patients with hepatitis C. *Hepatol. Res.* 2006; **36**: 288–93.
- 17 Yada N, Kudo M, Chung H *et al.* PEG-IFN α /RBV combination therapy for chronic hepatitis C patients increases serum ferritin level while it improves sustained viral response rate. *Intervirology* 2010; **53**: 60–5.
- 18 Kato J, Miyanishi K, Kobune M *et al.* Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. *J. Gastroenterol.* 2007; **42**: 830–6.
- 19 Fujita N, Sugimoto R, Takeo M *et al.* Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. *Mol. Med.* 2007; **13**: 97–104.
- 20 Fujita N, Sugimoto R, Motonishi S *et al.* Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. *J. Hepatol.* 2008; **49**: 702–10.
- 21 Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. *Rapid Commun. Mass Spectrom.* 2007; **21**: 4033–8.
- 22 Hosoki T, Ikuta K, Shimonaka Y *et al.* Heterogeneous expressions of hepcidin isoforms in hepatoma-derived cells detected using simultaneous LC-MS/MS. *Proteomics Clin. Appl.* 2009; **3**: 1256–64.
- 23 Radaeva S, Jaruga B, Hong F *et al.* Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. *Gastroenterology* 2002; **122**: 1020–34.
- 24 Testoni B, Schinzari V, Guerrieri F, Gerbal-Chaloin S, Blandino G, Levrero M. p53-paralog DNp73 oncogene is repressed by IFN α /STAT2 through the recruitment of the Ezh2 polycomb group transcriptional repressor. *Oncogene* 2011; **30**: 2670–8.
- 25 Terawaki S, Chikuma S, Shibayama S *et al.* IFN- α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. *J. Immunol.* 2011; **186**: 2772–9.
- 26 Thibault DL, Graham KL, Lee LY, Balboni I, Hertzog PJ, Utz PJ. Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus. *Arthritis Res. Ther.* 2009; **11**: R112.
- 27 Ryan JD, Altamura S, Devitt E *et al.* Pegylated interferon- α induced hypoferrremia is associated with the immediate response to treatment in hepatitis C. *Hepatology* 2012; **56**: 492–500.
- 28 Ikuta K, Zak O, Aisen P. Recycling, degradation and sensitivity to the synergistic anion of transferrin in the receptor-independent route of iron uptake by human hepatoma (HuH-7) cells. *Int. J. Biochem. Cell Biol.* 2004; **36**: 340–52.

Original Article

Augmented hepatic Toll-like receptors by fatty acids trigger the pro-inflammatory state of non-alcoholic fatty liver disease in mice

Koji Sawada,¹ Takaaki Ohtake,¹ Takumu Hasebe,¹ Masami Abe,¹ Hiroki Tanaka,² Katsuya Ikuta,¹ Yasuaki Suzuki,⁴ Mikihiro Fujiya,¹ Chitomi Hasebe³ and Yutaka Kohgo¹

¹Department of Medicine, Division of Gastroenterology and Hematology/Oncology, ²Department of Gastrointestinal Immunology and Regenerative Medicine, Asahikawa Medical University, ³Department of Gastroenterology, Asahikawa Red Cross Hospital, Asahikawa, and ⁴Department of Gastroenterology, Nayoro City General Hospital, Nayoro, Japan

Aim: There is considerable evidence that intestinal microbiota are involved in the development of metabolic syndromes and, consequently, with the development of non-alcoholic fatty liver disease (NAFLD). Toll-like receptors (TLRs) are essential for the recognition of microbiota. However, the induction mechanism of TLR signals through the gut-liver axis for triggering the development of non-alcoholic steatohepatitis (NASH) or NAFLD remains unclear. In this study, we investigated the role of palmitic acid (PA) in triggering the development of a pro-inflammatory state of NAFLD.

Methods: Non-alcoholic fatty liver disease was induced in mice fed a high fat diet (HFD). The mice were killed and the expression of TLRs, tumor necrosis factor (TNF), interleukin (IL)-1 β , and phospho-interleukin-1 receptor-associated kinase 1 in the liver and small intestine were assessed. In addition, primary hepatocytes and Kupffer cells were treated with PA,

and the direct effects of PA on TLRs induction by these cells were evaluated.

Results: The expression of inflammatory cytokines such as TNF, IL-1 β , and TLR-2, -4, -5, and -9 was increased in the liver, but decreased in the small intestine of HFD-fed mice *in vivo*. In addition, the expression of TLRs in primary hepatocytes and Kupffer cells was increased by treatment with PA.

Conclusion: In the development of the pro-inflammatory state of NAFLD, PA triggers the expression of TLRs, which contribute to the induction of inflammatory cytokines through TLR signals by intestinal microbiota.

Key words: fatty acids, gut-liver axis, non-alcoholic fatty liver disease, pro-inflammatory state, Toll-like receptor

INTRODUCTION

NON-ALCOHOLIC FATTY LIVER disease (NAFLD) is a form of steatosis with or without inflammation of the liver, and it is not related to excessive alcohol intake. NAFLD includes both simple steatosis and non-alcoholic steatohepatitis (NASH), the latter developing further into cirrhosis and hepatocellular carcinoma.¹ NAFLD is one of the most common liver diseases world-

wide and is considered to be related to obesity, insulin resistance, and metabolic syndrome.²

A two-hit theory has been proposed to explain the pathogenesis of NASH.³ First, simple steatosis is induced by obesity and insulin resistance. Second, NASH develops by several hits, including adipocytokines, iron, and bacterial endotoxins/lipopolysaccharide (LPS) derived from gram-negative bacteria.^{4–6}

Toll-like receptors (TLRs) recognize pathogen- and endogenous damage-associated molecular patterns and activate nuclear factor- κ B (NF- κ B), which induces pro-inflammatory cytokines/chemokines and type 1 interferon through phosphorylation of interleukin-1 receptor-associated kinase 1 (IRAK1) and IRAK4.⁷ Therefore, TLRs may play important roles in the activation of innate immunity. Among TLRs, TLR2, TLR4, TLR5, and

Correspondence: Dr Takaaki Ohtake, Department of Medicine, Division of Gastroenterology and Hematology/Oncology, Asahikawa Medical University, 2-1 Midorigaoka Higashi, Asahikawa 078-8510, Japan. Email: totake@asahikawa-med.ac.jp
Received 30 January 2013; revision 18 June 2013; accepted 1 July 2013.

TLR9 were identified as bacterial recognition receptors capable of recognizing lipopeptide, LPS, flagellin, and CpG-DNA, respectively.⁸ Recently it was reported that TLR signal pathways, the ligands of which are bacterial components, play an important role in the pathogenesis of alcoholic liver disease and NASH.⁹ In particular, the association between TLR4 signal pathways and the development of NASH was investigated.^{6,10,11} More recently, Miura *et al.* reported decreased levels of steatohepatitis and liver fibrosis in TLR9 knockout mice compared with those in wild-type mice in a choline-deficient amino acid-defined (CDA) diet-induced NASH model.¹² In contrast, in TLR2-deficient mice fed a methionine- and choline-deficient (MCD) diet, an increased level of liver injury was noted, suggesting a potential protective role of TLR2 in fatty liver.⁶

An increasing proportion of the general population suffers from obesity, which is an emerging global problem along with its related disorders such as metabolic syndrome. Much recent evidence shows that microbiota are associated with these conditions.^{13–19} In the intestine, TLRs are typically expressed in the epithelial cells and are involved in the production of immunoglobulin A (IgA), maintenance of tight junctions, proliferation of epithelial cells, and expression of antimicrobial peptides.²⁰ TLR5, which specifically recognizes flagellin, is involved in promoting the pathophysiology of inflammatory bowel disease.²¹ While the above reports suggest that intestinal TLRs play an important role in innate immunity of the gut, the association between their role in the small intestine and that in the development of NASH remains unclear.

The present study was based on hypernutrition and obesity and evaluated the significance of TLRs and their signaling in the liver and small intestine using a high-fat diet (HFD)-induced NAFLD mouse model. In addition, a gut-sterilized mouse model treated with antibiotics was used to confirm whether there is an association between intestinal microbiota and TLR expression.

METHODS

Animal studies

IN THE HFD group, 8-week-old male C57BL/6J mice (Charles River Japan, Tokyo, Japan) were fed a HFD containing 60% triglycerides with oleic acid (OA), palmitic acid (PA), and stearic acid (Table 1) (F2HFD2; Oriental Yeast Company, Tokyo, Japan). Control mice were fed a diet containing 5% triglycerides (MF; Oriental Yeast Company). All mice were maintained under controlled conditions (22°C; humidity, 50–60%, 12-h

Table 1 Composition of fatty acids in control diet and high fat diet

	Control diet (%)	High fat diet (%)
Oleic acid	No detect	30
Palmitic acid	No detect	25
Stearic acid	0.22	16
Palmitoleic acid	0.05	2.0
Myristic acid	0.03	1.5

light/dark cycle) with food and water *ad libitum*. Mice from both groups were killed at 4, 8, and 16 weeks for blood and tissue collection. These animals were fasted for 10-h before blood and tissue collection. After each mouse was anesthetized with diethyl ether and weighed, blood was collected by a cardiac puncture and subsequently assayed for biochemical parameters. The liver and small intestine were dissected, weighed, and frozen in liquid nitrogen. These samples were used later for histological and polymerase chain reaction (PCR) analysis. All experiments were performed in accordance with the rules and guidelines of the Animal Experiment Committee of Asahikawa Medical University.

Isolation and primary culture of hepatocytes and Kupffer cells

Mouse hepatocytes and Kupffer cells were isolated using a modified collagenase perfusion method.²² Briefly, the liver was perfused via the portal vein with Ca²⁺ and Mg²⁺ free Hank's balanced salt solution (HBSS(-)) at 39°C for 5 min at 10 mL/min, followed by HBSS(+) for 5 min at 10 mL/min supplemented with 0.05% collagenase (Wako, Tokyo, Japan). The liver was then removed, fragmented and vortexed for a few seconds. After filtration with mesh, the cell suspension was centrifuged at 500 rpm for 1 min. The cells in the pellet were minced twice and used as primary hepatocytes for culture in William's E medium with epidermal growth factor (5 µg), insulin (5 mg), L-glutamine, penicillin, streptomycin, and 10% fetal bovine serum (FBS). The supernatant was centrifuged at 500 rpm for 1 min at three to four times to remove any remaining hepatocytes. The supernatant was then minced twice and cultured in Dulbecco's modified Eagle's medium with penicillin, streptomycin, and 10% FBS. After 60 min, adhesion cells were used as Kupffer cells.

PA treatment

Isolated hepatocytes and Kupffer cells were treated with PA. PA complexed with 1% bovine serum albumin

(BSA) was added to the medium to attain final concentrations of 10 μ M and 100 μ M over 24 h.

Fat droplet evaluation

4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diazas-indacene (BODIPY 493/503, Invitrogen, Carlsbad, CA, USA) was added as a lipid probe overnight to the culture medium and fluorescent images were observed.

Biochemical analyses

Serum alanine aminotransferase (ALT) and free fatty acids were measured using the Automatic Analyzer 7180 (Hitachi High-Technologies Corporation, Tokyo, Japan).

Histopathological evaluation

Samples of remaining liver tissue were fixed in 10% formalin buffer, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E).

RNA isolation and first strand complementary DNA synthesis

Total RNA was isolated from the liver, small intestine, primary hepatocytes, and Kupffer cells using QIAGEN RNeasy Mini Kit (QIAGEN, Hilden, Germany). RNA was reverse-transcribed by RETROscript using Random decamers (Ambion, Austin, TX, USA). Detailed methods were performed according to the manufacturers' instructions.

Primer pairs of TLR-related molecules

Mouse 18srRNA was used as an endogenous amplification control. The use of this universally expressed house-keeping gene allows for correction of variations in the efficiency of RNA extraction and reverse transcription. TaqMan assays were used for specific primer and probe sets on TLR2, TLR4, TLR5, TLR9, tumor necrosis factor (TNF), interleukin (IL)-1 β , and 18srRNA (Applied Biosystems, Foster City, CA, USA).

Quantitative real-time PCR

The expression of TLR2, TLR4, TLR5, TLR9, IL-1 β , and TNF in mouse liver, small intestine, primary hepatocytes, and Kupffer cells was evaluated by quantitative real-time PCR (qPCR) (7300 Real-time PCR system; Applied Biosystems). In this method, all reactions were run in 96-well plates with a total volume of 20 μ L. The reaction mixture consisted of 10 μ L TaqMan Universal PCR Master mix, 1 μ L 18srRNA, 1 μ L primer, 5 μ L RNAase free water, and 3 μ L complementary DNA. The

PCR reaction involved the following steps: (i) 50°C for 2 min to prevent carryover of DNA, (ii) 95°C for 10 min to activate polymerase, and (iii) 40 cycles each of 95°C for 15 s, 60°C for 15 s, and 72°C for 45 s. qPCR data were analyzed by the comparative CT method.

Immunohistochemistry/ immunocytochemistry

Immunohistochemistry using F4/80 as a macrophage marker was performed on cryostatically sectioned liver and staining was performed by immunofluorescence. The sections were fixed in 2% paraformaldehyde for 10 min and washed three times with PBS for 5 min. Furthermore, sections for F4/80 were blocked with 3% BSA/PBS for 1 h at room temperature, followed by incubation with monoclonal antibody against F4/80 (Abcam, Cambridge, MA, USA) 1:100 diluted in 3% BSA/PBS for 1 h at room temperature. After washing, F4/80 slides were incubated with 1:200 diluted Alexa Fluor 488 goat anti-rat IgG (Invitrogen) for 1 h at room temperature and washed.

Immunocytochemical staining was also performed using the immunofluorescence method. After the chamber slides in which primary Kupffer cells had been cultured were washed twice with PBS for 5 min, primary Kupffer cells were fixed in 2% paraformaldehyde for 20 min and washed twice with PBS for 5 min. Primary Kupffer cells were then incubated with 0.1% Triton X-100 in PBS for 2 min to permeabilize the membranes and washed twice with PBS. The slides for phospho-interleukin-1 receptor-associated kinase1 (pIRAK1; Abcam) were blocked with 3% BSA/PBS for 1 h at room temperature, followed by incubation with monoclonal antibody against pIRAK1 diluted 1:500 in 3% BSA/PBS for 1 h at room temperature. After washing, the slides were incubated with 1:500 diluted Alexa Fluor 594 goat anti-rat IgG (Invitrogen) for 1 h at room temperature and washed.

Western blotting analysis

Protein expression of pIRAK1, the key mediator in the TLR signaling pathway,²³ in the liver (30 μ g), small intestine (30 μ g) was studied by Western blot analysis. Protein concentrations were measured by the Bradford method using the Pierce BCA Protein Assay kit (Thermo Scientific, Rockford, IL, USA) according to the manufacturer's instructions. Separation of 30 μ g of protein was then performed by 12% Mini PROTEAN TGX Precast Gels (Bio-Rad, Hercules, CA, USA). After electrophoresis, proteins were transferred to nitrocellulose membranes (Amersham Life Science Piscataway, NJ, USA),

blocked in 5% skim milk, and 0.2% Tween20 in PBS (PBS-T) for 1 h at room temperature, reacted overnight at 4°C with either rabbit polyclonal anti-pIRAK1 (Abcam) or β -actin (BD Biosciences) as a control, washed with 0.2% PBS-T, reacted with secondary antibody horseradish peroxidase-conjugated anti-rabbit IgG and anti-mouse IgG (RD, Minneapolis, MN, USA) for 1 h, and washed with PBS-T. After reaction with horseradish peroxidase-conjugated anti-rabbit and anti-mouse IgG, immune complexes were visualized by Super Signal West Pico Chemoluminescent Substrate (Thermo Scientific) according to the manufacturer's suggested procedure. pIRAK1 was analyzed by Image J software under the area, which compensated for β -actin.

Statistical analysis

The results are expressed as mean \pm standard error, with the two groups being analyzed by Student's *t*-test and datasets involving more than two groups being analyzed by analysis of variance (ANOVA). *P*-values of <0.05 were considered statistically significant.

Gut sterilization

Mice were treated with ampicillin (1 g/L; Sigma-Aldrich, St. Louis, MO, USA), neomycin (1 g/L; Sigma), metronidazole (1 g/L; Sigma), and vancomycin (500 mg/L; Sigma) in drinking water for 8 weeks.²⁴ This treatment was followed by feeding with HFD for further 8 weeks.

RESULTS

Fatty liver in HFD-fed mice

AT 16 WEEKS, body weight and serum ALT levels were significantly higher in the HFD-fed mice (group F) than in those fed the control diet (group C) (body weight: C, 41.6 g; F, 51.0 g; serum ALT: C, 34 IU/L; F, 180 IU/L; Fig. 1a,b). Histopathological liver findings from group F demonstrated the absence of fat droplets at 4 weeks (Fig. 1c). However, the deposition of micronodular fat droplets in the centrilobular zone (Fig. 1d) was observed at 8 weeks and macronodular fat droplets and ballooning degeneration (Fig. 1e) were observed at 16 weeks, without any obvious infiltration of inflammatory cells. F4/80 staining for macrophage markers did not demonstrate an increased number of Kupffer cells (Fig. 1f,g).

Upregulation of cytokines in the fatty liver of HFD-fed mice

Histopathological examination of livers from group F demonstrated no obvious infiltration of inflammatory

cells, while mRNA levels of the inflammatory cytokines IL-1 β and TNF were significantly higher at 16 weeks (Fig. 2a,b).

Upregulation of TLRs in the fatty liver of HFD-fed mice

To confirm whether TLRs expression contributes to the induction of the abovementioned cytokines, we analyzed the mRNA of TLR2, TLR4, TLR5, and TLR9 that recognize bacterial components in the liver. The expression of these TLRs in the liver was not different between the two groups at 4 and 8 weeks, but at 16 weeks, this was significantly higher in the F group than in the C group (Fig. 2c–f). Western blot analysis also demonstrated that the expression of pIRAK1 in the liver was significantly upregulated in the F group compared with that in the C group at 16 weeks (Fig. 2g). These findings suggest that TLR upregulation contributes to the induction of cytokines and that the TLR signal pathway is genetically enhanced in simple steatosis in the absence of inflammation.

Downregulation of TLRs and cytokines in the small intestine of HFD-fed mice

The expression of TLRs that recognize bacterial components was significantly upregulated in the NAFLD liver. Because liver injury has a connection with exposure to bacterial components of intestinal origin, we then examined the small intestine of the NAFLD model mice. The mRNA expression of small intestinal TLR2, TLR4, TLR5, and TLR9 was not significantly different between the two groups at 4 and 8 weeks. Histopathological examination of the small intestine revealed no difference between the groups at 16 weeks, but, mRNA expression of all four TLRs was significantly lower in the F group than in the C group at 16 weeks (Fig. 3a–d). Expression of IL-1 β and TNF was also downregulated at 16 weeks (Fig. 3e,f). Moreover, pIRAK1 expression was also significantly decreased in the F group compared with that in the C group at 16 weeks (Fig. 3g). These findings indicate that the TLR signal pathway is genetically attenuated in the NAFLD small intestine.

Antibiotic treatment improved steatosis and TLRs expression in the liver of HFD-fed mice

Small intestinal bacterial overgrowth (SIBO) was reported to coexist with NASH,^{14,25} and the following factors can predispose to SIBO: morbid obesity,²⁶ aging,²⁷ concurrent use of proton pump inhibitors,²⁸ and abnormal small intestinal motility.²⁹ Therefore, we hypothesized that attenuation of TLR signal




Figure 1 Body weight, serum alanine aminotransferase (ALT), and histopathological findings in high fat diet (HFD)-fed and control mice. Body weight (a) and serum ALT levels (b) were significantly higher in HFD-fed mice (F) than in controls at 16 weeks. Histopathological liver findings in F mice at 4, 8, and 16 weeks with H&E staining ($\times 400$, 4 weeks [c]; 8 weeks [d]; 16 weeks [e]). Micronodular fat droplets deposited in hepatocytes in the centrilobular zone at 8 weeks (d). Macronodular fat droplets and ballooning degeneration were marked at 16 weeks, but no obvious infiltration of inflammatory cells was observed (e). F4/80 staining for macrophage marker did not demonstrate any increase in Kupffer cells (control (f); 16 weeks (g); white arrows indicate Kupffer cells, $\times 400$). (* $P < 0.05$).




Figure 2 mRNA expression of inflammatory cytokines and Toll-like receptors in the liver of high fat diet (HFD)-fed and control mice. mRNA expression of interleukin (IL)-1 β (a), and tumor necrosis factor (TNF) (b) was significantly higher in the liver of HFD-fed mice (F) than in that of controls (C) at 16 weeks. The expression of TLR2 (c), TLR4 (d), TLR5 (e), and TLR9 (f) mRNA was significantly higher in the liver in group F than in group C at 16 weeks. Western blot analysis demonstrated a higher expression of pIRAK1 in the liver in group F than in group C at 16 weeks (g). (* $P < 0.05$, ** $P < 0.01$).




Figure 3 mRNA expression of inflammatory cytokines and Toll-like receptors in the small intestine of high fat diet (HFD)-fed and control mice. mRNA expression of TLR2 (a), TLR4 (b), TLR5 (c), and TLR9 (d) in the small intestine was significantly lower in HFD-fed mice (F) than in control mice (C) at 16 weeks. mRNA expression of IL-1β (e) and TNF (f) in the small intestine was also lower in group F than in group C at 16 weeks. Western blot analysis demonstrated a lower expression of phospho-interleukin-1 receptor-associated kinase1 (pIRAK) in the small intestine in group F than in group C at 16 weeks (g). (**P* < 0.05, ***P* < 0.01).

pathways may induce immunotolerance, altered levels of microbiota, and bacterial overgrowth in the NAFLD small intestine. To investigate whether intestinal microbiota contribute to TLR expression, we eliminated them by treatment with non-absorbable broad-spectrum antibiotics.²⁴

Body weight, serum ALT levels, and serum free fatty acids levels were significantly decreased in mice fed HFD and administered antibiotics (FA) compared with that in the mice fed HFD and water only (FC) (body weight: control diet and water only (CC), 28.9 g; control diet and antibiotics (CA), 28.6 g; FA, 34.7 g; FC, 51.9 g; serum ALT: CC, 19.5 IU/L; CA, 23.4 IU/L; FA, 34.7 IU/L; FC, 147.6 IU/L; serum free fatty acids: CC, 677.1 μ Eq/L; CA, 818.7 μ Eq/L; FA, 635.6 μ Eq/L; FC, 962.7 μ Eq/L; Fig. 4a–c). Histopathological findings from the livers of FC mice demonstrated the deposition of macronodular fat droplets in the centrilobular area and ballooning degeneration of hepatocytes. In contrast, FA mice showed a marked decrease in steatosis compared with the FC mice (Fig. 4d–g). The expression of TLRs (Fig. 5a–d) and inflammatory cytokines (Fig. 5e,f) was also significantly lower in the liver of FA mice than in that of FC mice. These data indicate associations among intestinal microbiota, TLR expression, and fatty acid metabolism.

Antibiotic treatment did not alter TLRs expression in the small intestine of HFD-fed mice

In the small intestine of mice fed the control diet, the expression of TLR2, TLR4, TLR5, and TLR9 was downregulated by antibiotic treatment (Fig. 6). However, contrary to expectations, the expression in HFD-fed mice did not alter (Fig. 6). These data suggest that microbiota contribute to TLRs expression in the small intestine of mice fed the control diet but not in that of mice fed HFD.

PA upregulated TLR2, TLR4, TLR5, and TLR9 expression in primary Kupffer cells

Because both serum free fatty acids and TLR expression were coincidentally suppressed in the intestinal bacterial eradication model, we examined whether fatty acids would alter TLR expression. First, we investigated TLR expression in primary Kupffer cells.

To determine the effects of fatty acids on TLR expression in Kupffer cells, PA was added to primary Kupffer cells for 24 h, where it induced the deposition of fat droplets (Fig. 7a,b). The mRNA expression of TLR2, TLR4, TLR5, and TLR9 was significantly higher in

primary Kupffer cells treated with 10 μ M PA for 24 h than in control cells (Fig. 7c).

Immunocytochemistry demonstrated that the expression of pIRAK1 was strongly positive in primary Kupffer cells with fat deposits (Fig. 7d). mRNA expression in IL-1 β was not significantly different, but the expression of TNF was significantly higher in primary Kupffer cells exposed to 10 μ M PA for 24 h than in controls (Fig. 7e,f). These findings indicate that PA may enhance the TLR signal pathway in Kupffer cells.

PA upregulated TLR4 and TLR9 expression in primary hepatocytes

Second, we examined TLR expression in primary hepatocytes treated with 100 μ M PA for 24 h, which induced the deposition of fat droplets in these cells (Fig. 8a,b). mRNA expression of TLR4 and TLR9, but not that of TLR2 and TLR5 was significantly upregulated in primary hepatocytes treated with 100 μ M PA for 24 h (Fig. 8c). The expression of IL-1 β and TNF was significantly upregulated in primary hepatocytes treated with 100 μ M PA for 24 h (Fig. 8d,e). These findings suggest that PA can, at least in part, enhance TLR signal pathways in hepatocytes.

DISCUSSION

MICE FED THE MCD diet demonstrated steatosis, macrophages accumulation, and clustering of neutrophils in the liver. Consequently, the expression of TLR4 and TNF- α was increased; however, the destruction of Kupffer cells prevented an increase in TLR4 expression,¹⁰ indicating that increased expression levels had contributed to infiltration of inflammatory cells. It was reported that fatty liver in NASH resulted in increased liver injury and inflammation following intraperitoneal LPS injection in an MCD diet-induced NASH mouse model, suggesting that the MCD diet-induced NASH liver is sensitive to the TLR4 ligand LPS.⁶ In our present model, mice fed HFD for 16 weeks developed steatosis with no histological evidence of inflammation and fibrosis, which is known as simple steatosis. However, the expression of inflammatory cytokines was upregulated, and our findings established that this was the mechanism by which TLR signal pathways were upregulated in the NAFLD liver prior to the development of steatohepatitis. Moreover, F4/80 staining revealed that this upregulation was not affected by an altered number of Kupffer cells but by changes in their activity in regard to inflammatory cytokine production. Our findings show that simple steatosis prior to NASH




Figure 4 Body weight, serum alanine aminotransferase (ALT) levels, serum free fatty acids, and histopathological findings in high fat diet (HFD)-fed and control mice with or without antibiotic administration. CC, control diet and water only; CA, control diet and antibiotics; FC, HFD and water only; FA, HFD and antibiotics. Body weight was significantly higher in FC mice than in FA mice (a). Serum ALT levels (b) and serum free fatty acids levels (c) were also suppressed in FA mice compared with those in FC mice. Histopathological liver findings for CC (d), CA (e), FC (f), and FA (g) mice with H&E staining ($\times 100$) demonstrated macronodular fat droplets and ballooning degeneration in the liver in FC mice, whereas steatosis was obviously suppressed in FA mice. (* $P < 0.05$, ** $P < 0.01$).




Figure 5 mRNA expression of Toll-like receptors and inflammatory cytokines in the liver in high fat diet (HFD)-fed and control mice with or without antibiotic administration. Expression of TLR2 (a), TLR4 (b), TLR5 (c), and TLR9 (d) was suppressed more in the liver of FA mice than in the liver of FC mice. Expression of IL-1 β (e) and tumor necrosis factor (TNF) (f) was also suppressed. (* $P < 0.05$, ** $P < 0.01$).




Figure 6 mRNA expression of Toll-like receptors in the small intestine of high fat diet (HFD)-fed and control mice with or without antibiotic administration. Toll-like receptors (TLRs) expression was not altered by antibiotic treatment in non-alcoholic fatty liver disease (NAFLD) small intestine (TLR2 (a), TLR4 (b), TLR5 (c), and TLR9 (d)). (* $P < 0.05$, ** $P < 0.01$) (NS, not significant).

demonstrates upregulation of TLR signal pathways and may be more sensitive to the ligands of intestinal microbial components. Bertola *et al.* reported that the expression of TLRs and certain cytokines/chemokines in genes was upregulated in biopsy specimens of morbidly obese patients with histologically normal liver or severe steatosis with or without NASH,³⁰ and our findings from this animal study concur with this.

Although many studies have examined the association between TLR signal pathways and the pathogenesis of NASH, these reports focused mainly on hepatocytes,

Kupffer cells, and hepatic stellate cells.^{6,10,12,31} However, small intestinal microbiota are the cause of liver damage in NASH, and to our knowledge, this is the first report to investigate the expression of intestinal TLR signal pathways in NAFLD model and to reveal a discrepancy in TLRs expression in the gut-liver axis. The microbial TLR signal pathway and downstream cytokines were downregulated in the small intestine of NAFLD model and this downregulation may contribute to imbalance of the immune system and, consequently, alter the microflora component ratio and induce SIBO with NAFLD.




Figure 7 mRNA expression of Toll-like receptors and inflammatory cytokines in primary Kupffer cells treated with palmitic acid (PA). Treatment by PA for 24 h induced deposition of fat droplets in primary Kupffer cells (a: control, b: treatment with 10 μM PA, BODIPY (green), 4'6'-diamidino-2-phenylindole dihydrochloride (DAPI) [blue]). The expression of TLR2, TLR4, TLR5, and TLR9 was significantly higher in primary Kupffer cells treated with 10 μM PA for 24 h (C: control) (c). Immunocytochemistry demonstrated that the expression of phospho-interleukin-1 receptor-associated kinase1 (pIRAK1) was strongly positive in fat deposited primary Kupffer cells treated with 10 μM PA for 24 h (d: BODIPY (green), pIRAK1 (red) and DAPI (blue)). Arrow: Kupffer cells deposited in fat droplets. Arrow head: Kupffer cell deposited in absence of fat droplets. Tumor necrosis factor (TNF) expression was significantly higher in primary Kupffer cells treated with 10 μM PA for 24 h (IL-1β (e), TNF (f)) (* $P < 0.05$, ** $P < 0.01$).

We used a mouse model gut-sterilized with antibiotics to confirm whether there is an association between gut microbiota and TLR expression in NAFLD. In our model, oral caloric intake was not significantly different between FA and FC mice, but, body weight, serum ALT levels, and serum free fatty acids levels were significantly suppressed in the FA mice. Furthermore, histopathological findings showed a marked decrease in steatosis in this group. Interestingly, the expression of TLRs and downstream cytokines was suppressed in FA mice compared with that in FC mice. In contrast, in an ethyl alcohol-induced liver injury model, liver TLR expression was found to be independent of gut microbiota despite a decrease in fatty liver and liver injury by antibiotic administration.⁹ Our findings suggest that, directly or

indirectly, gut microbiota contribute to TLR expression in the liver of the NAFLD model. Because antibiotics administration also decreased serum free fatty acids in FA mice, we focused on the association between fatty acid metabolism and gut microbiota. There are three reasons for the suppression of serum free fatty acids in FA mice. The first is a decrease in adipocytes accompanied by suppression of increasing body weight. This may be explained by the fact that obesity-associated microbiota, which increase the capacity to harvest energy from the diet, were eradicated by antibiotics.¹³ We investigated 16 s rRNA based analysis of fecal microbiota by the terminal restriction fragment length polymorphism method and confirmed alteration in fecal microbiota of FA mice compared with that of FC




Figure 8 mRNA expression of Toll-like receptors and inflammatory cytokines in primary hepatocytes treated with palmitic acid (PA). Treatment by PA for 24 h induced the deposition of fat droplets in primary hepatocytes (a: control, b: treatment with 100 μM PA, BODIPY (green), 4′6′-diamidino-2-phenylindole dihydrochloride (DAPI) [blue]). The expression of TLR4 and TLR9 mRNA was significantly upregulated in primary hepatocytes treated with 100 μM PA for 24 h (C: control) (c). The expression of tumor necrosis factor (TNF) and interleukin (IL)-1β was significantly higher in primary hepatocytes treated with 100 μM PA for 24 h (IL-1β (d), TNF [e]) (* $P < 0.05$, ** $P < 0.01$).

mice (data not shown). The second reason is a decrease in the release of free fatty acids from adipocytes. In obese individuals, it has been reported that gut microbiota can suppress the expression of fasting-

induced adipose factor (Fiaf), which increases the activity of lipoprotein lipase, leading to the production of triglyceride storage in adipocytes and an increased supply of fatty acids.³² The expression of intestinal Fiaf was significantly upregulated in FA mice compared with FC mice in our experiment (data not shown), indicating that gut-sterilization may contribute to a reduction in the release of serum free fatty acids from adipocytes through increased intestinal Fiaf expression. The third reason is a decrease in *de novo* liver lipogenesis. It is reported that microbiota can increase hepatic lipogenesis through the expression of sterol response element binding protein 1 (SREBP1) and carbohydrate response element binding protein (ChREBP).³³ The expression of both SREBP1 and ChREBP was significantly suppressed in FA mice compared with that in FC mice in our experiment (data not shown), indicating that the suppression of serum free fatty acids, at least in part, contributes to a decrease in hepatic *de novo* lipogenesis through the suppression of both SREBP1 and ChREBP. Our findings suggest both alteration in microflora and a decrease in *de novo* lipogenesis in the liver of the gut-sterilized model, but it is unknown whether the release of free fatty acids from adipocytes decreases.

Next, we hypothesized that fatty acids could alter TLRs expression in the liver. We showed that the expression of TLR2, TLR4, TLR5, TLR9, and TNF were significantly higher in primary Kupffer cells treated with PA than in control cells, while that of TLR4, TLR9, TNF, and IL-1β was upregulated in primary hepatocytes treated with PA. Although our *in vitro* study suggests that PA directly stimulates the induction of TLRs, others report that saturated fatty acids (SFA) including PA stimulate NFκB promoter activity through the activation of the TLR signal pathway. It is also reported that SFA plays a role as TLR4 ligand.^{34,35} Therefore, the induction of downstream cytokines may have contributed to both the upregulation of TLRs and stimulation of TLR4 by PA. These findings suggest that Kupffer cells and hepatocytes are susceptible to bacterial components via upregulation of TLRs by PA in the pro-inflammatory state of NAFLD.

In contrast, although TLRs expression in the small intestine of HFD-fed mice was not altered by antibiotic treatment, it was downregulated in control mice. Therefore, we hypothesized that luminal HFD itself could attenuate TLRs expression in the small intestine. Caco2 cells that are human epithelial cell lines treated with PA or OA showed lower expression of TLR2, TLR5, and TLR9 compared with control cells (data not shown). These data suggest that fatty acids may partly contribute

to the attenuation of TLRs expression in the small intestine.

In conclusion, TLRs expression was downregulated in the NAFLD small intestine, and this may be contributed to an increase in free fatty acids through alteration of gut microbiota. In contrast, the hepatic TLR signal pathway was upregulated and susceptible to microbial components by increased free fatty acids in the pro-inflammatory state of NAFLD. Our findings suggest that discrepancy in TLR signals in the gut-liver axis may be associated with the pathogenesis of progression to NASH through an increase in free fatty acids. Because there is no specific treatment for human NASH, early intervention in the pro-inflammatory state may be important for the prevention of its development from simple steatosis. Because free fatty acids play an important role in the development of the pro-inflammatory state of NAFLD, we consider that both fatty acid metabolism and gut microbiota in the pro-inflammatory state may be useful targets for preventive treatment against NASH development.

ACKNOWLEDGMENTS

THIS WORK WAS supported, in part, by Grants-in-Aid for Young Scientists (B) provided by the Ministry of Education, Culture, Sports, Science, and Technology, Japan.

REFERENCES

- Ludwig J, Viggiano TR, McGill DB, Brewer NS. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* 1980; 55: 482–8.
- Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. *Semin Liver Dis* 2008; 28: 339–50.
- Day CP, James OF. Steatohepatitis: a role of two “hit”? *Gastroenterology* 1998; 114: 842–5.
- Marra F, Bertolani C. Adipokines in liver disease. *Hepatology* 2009; 50: 957–62.
- George DK, Goldwurm S, MacDonald GA *et al*. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. *Gastroenterology* 1988; 114: 311–18.
- Szabo G, Velayudham A, Romics L Jr, Mandrekar P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptor 2 and 4. *Alcohol Clin Exp Res* 2005; 29 (11 Suppl): 140S–5S.
- Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. *Gastroenterology* 2008; 48: 322–35.
- Takeda K, Akira S. TLR signaling pathway. *Semin Immunol* 2004; 16: 3–9.
- Gustot T, Lemmers A, Moreno C *et al*. Differential liver sensitization to Toll-like receptor pathways in mice with alcoholic fatty liver. *Hepatology* 2006; 43: 989–1000.
- Rivera CA, Adegoyage P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. *J Hepatol* 2007; 47: 571–9.
- Imajo K, Fujita K, Yoneda M *et al*. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin mediated signaling. *Cell Metab* 2012; 16: 44–54.
- Miura K, Kodama Y, Inokuchi S *et al*. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1 β in mice. *Gastroenterology* 2010; 139: 323–34.
- Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature* 2006; 444: 1027–31.
- Shanab AA, Scully P, Crosbie O *et al*. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. *Dig Dis Sci* 2011; 56: 1524–34.
- Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. *Nature* 2006; 444: 1022–3.
- Cani PD, Bibiloni R, Knauf C *et al*. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high fat diet induced obesity and diabetes in mice. *Diabetes* 2008; 57: 1470–81.
- Bajzer M, Seeley RJ. Obesity and gut flora. *Nature* 2006; 444: 1009–10.
- de La Serre CB, Ellis CL, Lee J, Hartman AL, Rutledge JC, Raybould EE. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota gut inflammation. *Am J Physiol Gastrointest Liver Physiol* 2010; 299: G440–8.
- Vijay-Kumar M, Aitken JD, Carvalho A *et al*. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. *Science* 2010; 328: 228–31.
- Santaolalla R, Fukata M, Abreu M. Innate immunity in the small intestine. *Curr Opin Gastroenterol* 2011; 27: 125–31.
- Lodes MJ, Cong Y, Elson CO *et al*. Bacterial flagellin is a dominant antigen in Crohn disease. *J Clin Invest* 2004; 113: 1296–306.
- Munthe-Kaas AC, Berq T, Seqlen PO, Seljelid R. Mass isolation and culture of rat Kupffer cells. *J Exp Med* 1975; 141: 1–10.
- Gottipati S, Rao NL, Fung-Leung WP. IRAK1: a critical signaling mediator of innate immunity. *Cell Signal* 2008; 20: 269–76.
- Seki E, Minicis SD, Osterreicher CH *et al*. TLR4 enhances TGF- β signaling and hepatic fibrosis. *Nat Med* 2007; 13: 1324–32.

- 25 Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumor necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. *Gut* 2001; 48: 206–11.
- 26 Sabate JM, Jouet P, Harnois F *et al.* High prevalence of small intestinal bacterial overgrowth with morbid obesity: a contributor to severe hepatic steatosis. *Obes Surg* 2008; 18: 371–7.
- 27 Pillotto A, Franceschi M, Del Favero G, Fabrello R, Di Mario F, Valerio G. The effect of aging on oro-cecal transit time in normal subjects and patients with gallstone disease. *Aging (Milano)* 1995; 7: 234–7.
- 28 Elphick DA, Chew TS, Higham SE, Bird N, Ahmad A, Sanders DS. Small bacterial overgrowth in symptomatic older people: can it be diagnosed earlier? *Gerontology* 2005; 51: 396–401.
- 29 Soza A, Riquelme A, Gonzalez R *et al.* Increased oro-cecal transit time in patients with nonalcoholic fatty liver disease. *Dig Dis Sci* 2005; 50: 1136–40.
- 30 Bertola A, Bonnafous S, Anty R *et al.* Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. *PLoS ONE* 2010; 5: e13577.
- 31 Rivera CA, Gaskin LT, Allman M *et al.* Toll-like receptor 2 deficiency enhances non-alcoholic steatohepatitis. *BMC Gastroenterol* 2010; 10: 52.
- 32 Backhed F, Ding H, Wang T *et al.* The gut microbiota as an environmental factor that regulates fat storage. *Proc Natl Acad Sci U S A* 2004; 101: 15718–23.
- 33 Prakash S, Rodes L, Coussa-Charley M, Duchesneau CT. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. *Biologics* 2011; 5: 71–86.
- 34 Lee JY, Plakidas A, Lee WH *et al.* Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. *J Lipid Res* 2003; 44: 909–16.
- 35 Lee JY, Gao Z, Youn HS *et al.* Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. *J Biol Chem* 2003; 278: 37041–51.

Review Article

New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions

Makoto Chuma,^{1,2*} Katsuimi Terashita,¹ and Naoya Sakamoto^{1*}¹Department of Gastroenterology and Hepatology, Hokkaido University, Sapporo, and ²Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan

Hepatocellular carcinoma (HCC) can be lethal due to its aggressive course and lack of effective systemic therapies for advanced disease. Sorafenib is the only systemic therapy that has demonstrated an overall survival benefit in patients with advanced HCC, and new agents for treatment of advanced HCC are needed. The multiple pathways involved in HCC oncogenesis, proliferation and survival provide many opportunities for the development of molecularly targeted therapies. Molecular targets of interest have expanded from angiogenesis to cancer cell-directed oncogenic signaling pathways for treatment of advanced HCC. Agents targeting vascular endothelial growth factor receptor, epidermal growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, c-mesenchymal-epithelial transition factor-1

and mammalian target of rapamycin signaling have been actively explored. This article focuses on the evaluation of molecular agents targeting pathogenic HCC and provides a review of recently completed phase III drug studies (e.g. involving sorafenib, sunitinib, brivanib, linifanib, erlotinib, everolimus, ramucirumab or orantinib) and ongoing drug studies (e.g. involving lenvatinib, regorafenib, tivantinib or cabozantinib) of molecularly targeted agents in advanced HCC, including a brief description of the biologic rationale behind these agents.

Key words: clinical trials, hepatocellular carcinoma, molecularly targeted therapy, novel agents, sorafenib

INTRODUCTION

HEPATOCELLULAR CARCINOMA (HCC) is the sixth most common cancer and the third most common cause of cancer-related deaths worldwide.¹ Because a considerable number of patients are diagnosed when the disease becomes advanced, only approximately a third of all HCC patients are eligible for potentially curative treatments, such as resection or transplantation.² Surgical resection or transplantation provides good survival rates (i.e. beyond 65% at 5 years).³ Unfortunately, the prognosis for patients with advanced stage HCC (Barcelona Cancer Liver Clinic [BCLC] stage C) is extremely poor, with a median

overall survival (OS) of 6.6 months.⁴ In advanced cases, only one systemic therapy is effective: the multikinase inhibitor sorafenib, which was approved by the U.S. Food and Drug Administration and which represented a breakthrough in the management of the disease.^{5,6} However, the median life expectancy of patients with HCC on sorafenib is only 1 year, indicating the clear need to improve their outcomes. Hepatocarcinogenesis is a complex multistep process involving a number of genetic and epigenetic alterations,^{7,8} our knowledge of several key molecular pathways implicated in HCC pathogenesis has revealed potential targets for therapeutic interventions, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth factor receptor (PDGFR), epidermal growth factor receptor (EGFR), RAS/RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathways. This review will examine our current understanding of these pathways as well as the efficacy and safety data pertaining to the most promising

Correspondence: Dr Makoto Chuma, Department of Gastroenterology and Hepatology, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan. Email: chumamakoto@gmail.com

*These authors contributed equally to this work.

Received 16 September 2014; revision 15 November 2014; accepted 25 November 2014.

molecularly targeted agents beyond sorafenib. In this article, we first describe the pathogenesis of HCC and then provide an update on the recent data on clinical trials using molecularly targeted agents.

PATHOGENESIS OF HCC

HEPATOCELLULAR CARCINOMA IS a hypervascular tumor, and the central role of angiogenesis in its initiation, growth and subsequent dissemination to other tissues is well recognized. Angiogenesis in HCC is mediated by a complex network of growth factors, acting on both tumor cells and endothelial cells. The most widely recognized angiogenic factors are VEGF, FGF and PDGF.⁹ These activate receptor tyrosine kinases (RTK) and the RAS/RAF/MEK/ERK pathway and the PI3K pathway in endothelial cells (Fig. 1).^{10,11} VEGF and its receptors play a major role in tumor angiogenesis. In fact, VEGF is a potent permeability factor that promotes

cell migration during invasion and acts as an endothelial growth factor that stimulates endothelial cell proliferation, inducing the budding of new blood vessels around the growing tumor masses. In human specimens and serum, increased expression of VEGF correlates with aggressive behavior of HCC and poor prognosis.¹² FGF and its family of receptors has also been implicated in HCC growth, invasion and angiogenesis.¹³ While VEGF is the main driver of tumor angiogenesis, there is cross-talk between VEGF and FGF signaling in angiogenesis.¹⁴ The upregulation of FGF has been suggested to mediate resistance to anti-VEGF receptor (VEGFR) therapy. The great majority of the HCC cases have overexpression of at least one FGF and/or FGF receptor (FGFR).¹⁰ Hence, blocking the FGFR is another potentially important approach for the treatment of HCC. PDGF is involved in the development of immature tumor vessels,¹⁵ while angiopoietins exert their action via stabilization of vessels by recruiting surrounding pericytes and smooth




Figure 1 Schematic diagram of key molecular targets and targeted agents in hepatocellular carcinoma. [#]Approved globally in patients with advanced hepatocellular carcinoma (HCC). [†]Completed studies of phase III of molecularly targeted agents in advanced HCC. ^{*}Ongoing studies of phase III of molecularly targeted agents in advanced HCC. c-MET, c-mesenchymal-epithelial transition factor-1; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; Flt-3, Fms-like tyrosine receptor kinase-3; Gab1, GRB2-associated binding protein 1; Grb2, growth factor receptor bound protein 2; HER-1, human epidermal growth factor receptor-1; HGF, hepatocyte growth factor; MEK, mitogen-activated protein kinase/ERK kinase; mTOR, mammalian target of rapamycin; PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor; PI3K, phosphatidylinositol 3-kinase; RET, rearranged during transfection; SCFR, stem cell growth factor receptor kit; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.

muscle cells.¹⁶ PDGF is involved in fibrogenesis, angiogenesis and tumorigenesis.^{17,18} PDGF expression is upregulated in the early stages of chronic hepatitis, suggesting its association with the development of fibrosis in chronic hepatitis C.¹⁹ From a therapeutic point of view, inhibition of these targets has been shown to diminish the vascularity of tumors in preclinical studies.

Several intracellular signaling pathways are involved in HCC pathogenesis; the most studied are the PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways. The PI3K/AKT/mTOR axis is involved in multiple cellular processes, including survival and proliferation.²⁰ This pathway mediates its effects through activation of various tyrosine kinase receptors, such as VEGFR, EGFR and PDGFR, which in turn recruit and activate PI3K. The activation of PI3K will lead to a cascade of activation of downstream effectors, leading to activation of mTOR (Fig. 1). The activation of the mTOR pathway in HCC is associated with aggressive tumor behavior and decreased survival, which supports the efforts to target this pathway for therapeutic interventions.²¹ RAS/RAF/MEK/ERK signaling regulates many important cellular processes, such as proliferation, differentiation, angiogenesis, survival and cell adhesion.²² Importantly, the RAS/RAF/MEK/ERK pathway is constitutively activated in HCC.²³

Apart from these major signal pathways in the pathogenesis of HCC, the hepatocyte growth factor (HGF)/c-mesenchymal-epithelial transition factor-1 (c-MET) pathway is involved in tumor growth, invasion and angiogenesis in various types of cancer.²⁴ c-MET is a tyrosine kinase receptor, with its ligand, HGF.²⁵ HGF-induced activation of c-MET ultimately leads to the activation of downstream effector molecules, including PI3K and ERK (Fig. 1).²⁶ Expression of the c-MET receptor protein is present in human HCC samples^{27–29} and has been shown to be a poor prognostic factor in patients with HCC. Therefore, therapeutics aimed at the c-MET receptor is a rational approach for HCC.

RESULTS OF PHASE III STUDIES

STUDIES ARE INVESTIGATING various agents for HCC, most of which target the previously described VEGF axis, FGF, PDGF, RAS/RAF/ERK and mTOR signaling pathways (Fig. 1). We describe these molecularly targeted agents and completed phase III trials. We also provide information on why phase III pivotal consecutive randomized controlled trials (RCT) in HCC did not meet the primary end-points (Table 1). Seven phase III trials reported negative results for first-line therapy (e.g.

with sunitinib, brivanib, linifanib or erlotinib) and second-line therapy (e.g. with brivanib, everolimus or ramucirumab). Five of these studies were designed to test for superiority (i.e. study of SUN 1170, SEARCH, BRISK-PS, EVOLVE-1, REACH), and two of these studies were designed to test for non-inferiority (i.e. study of BRISK-FL, 0100953) with a primary end-point of OS.

Sorafenib

Sorafenib is a multikinase inhibitor that inhibits serine/threonine kinases (BRaf and CRaf and VEGFR-1, -2 and -3), PDGFR- α and - β , and the stem cell factor receptor, c-kit. In the Sorafenib HCC Assessment Randomized Protocol (SHARP) study,⁵ a double-blind RCT with a primary end-point of OS, sorafenib significantly increased survival times of patients with HCC from 7.9 to 10.7 months (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.55–0.87; $P=0.001$). Among the enrolled patients, the proportion of patients with Child–Pugh liver function class A and B disease was 97% and 3%, respectively, while that with BCLC stage B and C disease was 17% and 83%, respectively. Sorafenib was the first systemic therapy to demonstrate a significant improvement in OS in patients with advanced HCC, and its subsequent approval represented a major breakthrough in the treatment of advanced HCC. A parallel phase III study was conducted in the Asia–Pacific region. Median OS was 6.5 months in the sorafenib arm and 4.2 months in the placebo arm (HR, 0.68; 95% CI, 0.50–0.93; $P=0.014$).⁶ Among the enrolled patients, the proportion of patients with Child–Pugh liver function class A and B disease was 97% and 3%, respectively, while that with BCLC stage B and C disease was 5% and 95%, respectively. Similar toxicity profiles were seen in both studies; sorafenib treatment was associated with increased rates of diarrhea, weight loss, hand–foot skin reaction and hypophosphatemia. Sorafenib is the first and only agent to demonstrate an OS benefit and to be approved by regulators globally in patients with advanced HCC.

Sunitinib

Sunitinib is another multikinase inhibitor with broad activity, inhibiting all VEGFR and PDGFR, c-kit, Fms-like tyrosine receptor kinase (Flt)3 and rearranged during transfection (RET). Sunitinib was evaluated against sorafenib in a large phase III trial.³⁰ All patients had Child–Pugh liver function class A disease, and the proportion of patients with BCLC stage B and C disease was 15% and 85%, respectively. Median time to progression (TTP) for sunitinib and sorafenib was 4.1 and 3.8